SCHEMBL2292344

SCHEMBL2292344

COC(=O)c1ccccc1NC(=O)c1ccc(COc2ccccc2OC)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.74
NPC1 O15118 3/20 0.74
RAB9A P51151 3/20 0.74
CASP3 P42574 2/20 0.74
SENP7 Q9BQF6 2/20 0.74
KMT2A Q03164 2/20 0.74
MEN1 O00255 1/20 0.74
MAPT P10636 6/20 0.67
ALDH1A1 P00352 4/20 0.67
TSHR P16473 5/20 0.64
CYP1A2 P05177 1/20 0.64
CYP2D6 P10635 1/20 0.64
CYP2C19 P33261 1/20 0.64
HSD17B10 Q99714 4/20 0.64
GAA P10253 3/20 0.64
MAPK1 P28482 1/20 0.64
HPGD P15428 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
RXRA P19793 1/20 0.60
ATM Q13315 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2290679 0.88 HPGD (0.78) KDM4ENPC1RAB9ACASP3SENP7
SCHEMBL13719210 0.83 TSHR (0.72) KDM4EKMT2AMEN1MAPTALDH1A1
SCHEMBL2291513 0.82 KDM4E (0.69) KDM4ENPC1RAB9ACASP3SENP7
SCHEMBL2291530 0.82 KDM4E (0.69) KDM4ENPC1RAB9AKMT2AMEN1
SCHEMBL2294806 0.82 ALDH1A1 (0.66) KDM4ENPC1RAB9ACASP3SENP7
SCHEMBL2290505 0.81 KDM4E (0.67) KDM4ENPC1RAB9ACASP3SENP7
SCHEMBL266327 0.81 CHEK1 (0.80) KDM4ENPC1RAB9AKMT2AMEN1
SCHEMBL9337435 0.81 TSHR (0.68) KDM4ENPC1RAB9AKMT2AMEN1
SCHEMBL2291128 0.80 KDM4E (0.66) KDM4ENPC1RAB9ACASP3SENP7
SCHEMBL2294814 0.80 SENP7 (0.74) KDM4ENPC1RAB9ACASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US claimed
JP-2008546661-A 2008-12-25 JP claimed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP claimed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO claimed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US claimed
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US disclosed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US disclosed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP disclosed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO disclosed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281810-A1 Novel anthranilic acid derivatives GPR84, HCAR1, GPR88 KDM4E 3357/4885NPC1 3594/4885RAB9A 1353/4885
US-20090247637-A1 Novel Anthranilic Acid Derivatives GPR84, GPR88, HCAR1 KDM4E 3132/4885NPC1 3210/4885RAB9A 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.